AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06323486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: active accelerated bilateral sequential theta burst stimulation and sham treatment
Description: We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions.
Study NCT06044532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
Study NCT06388252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotherapy with Intravenous Bleomycin
Description: ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
Study NCT06187324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: by th use of perio paper GCF was collected and Biomarkers level was estimated
Study NCT05669300 — intervention group
Intervention type: PROCEDURE
Intervention: Yilmaz Suturation
Description: uterine closure with Yilmaz Technique and single layer continue locked suturation
Study NCT05314881 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TNFS4, NCF gene
Description: study the gene polymorphisms from the blood sample of the included SLE patients
Study NCT06224517 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
Study NCT05390749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
Study NCT05390749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
Study NCT05390749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Study NCT04632394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Generation of computational model from cardiac MRI.
Description: Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
Study NCT04632394 — intervention group
Intervention type: PROCEDURE
Intervention: VT ablation
Description: Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
Study NCT05302310 — intervention group
Intervention type: OTHER
Intervention: integrated care
Description: i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed.
Study NCT05937529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream containing madecassoside and 5 % panthenol
Description: Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
Study NCT05937529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daylight PDT
Description: Daylight PDT performed with 2 hours of artifical indoor light.
Study NCT05937529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daylight PDT
Description: Daylight PDT performed with 2 hours of artifical indoor light.
Study NCT05866692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-2699a
Description: TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results
Study NCT05214937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
Study NCT05214937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FitBit Only
Description: Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
Study NCT05926063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison short vs extended EBAT treatment group
Description: This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
Study NCT04331990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physcial Therapy
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
Study NCT04331990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Mechanical Traction
Description: In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
Study NCT04331990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Mechanical Traction
Description: Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
Study NCT05390749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate 3.5g/m2 civ d1/cycle5-6
Study NCT04773327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim Injection
Description: 24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
Study NCT06147167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: individualized intermittent theta burst sitmulation (iTBS)
Description: Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
Study NCT06147167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard iTBS
Description: The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
Study NCT06147167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
Study NCT05103423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Study NCT05926063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison short vs extended EBAT treatment group
Description: This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
Study NCT05993793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fototherapy
Description: The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
Study NCT04702386 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
Study NCT04702386 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual interviews
Description: Interview led by the psychologist about being the child of a parent with CF
Study NCT03986190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Juntos
Description: Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period.
Study NCT05103423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Study NCT05057741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given.
Study NCT05362331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Application
Description: Internet based application
Study NCT05161637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 490mg or 588mg
Study NCT05161637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine 75mg
Study NCT05161637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 150mg
Study NCT05161637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL or 24mL
Study NCT06455436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard healing abutment
Description: Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
Study NCT06455436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized healing abutment
Description: Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
Study NCT05424991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comedy movie group
Description: The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
Study NCT06105203 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic-assisted total mesorectal excision
Description: TME will be performed with the assistance of robot in rectal cancer
Study NCT06105203 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic-assisted total mesorectal excision
Description: TME will be performed with the assistance of laparoscopy in rectal cancer
Study NCT04886193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
Description: * FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year.
Study NCT05511025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
Study NCT05103423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Study NCT05511025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection
Study NCT05511025 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HBA1C
Description: blood sample on EDTA
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides
Description: serum sample
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine analysis and urinary albumin-to-creatinine ratio
Description: Morning urine sample
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum creatinine and estimated glomerular filtration rate
Description: serum sample
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count
Description: blood sample on EDTA
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thyroid-stimulating hormone
Description: serum sample
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed
Description: serum sample
Study NCT04629261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of ECOBICI (public bicycle sharing program)
Description: Use of ECOBICI program with and without incentive.
Study NCT04729192 — intervention group
Intervention type: OTHER
Intervention: ObsQoR-10T Questionnaire
Description: The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
Study NCT05882279 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT05617937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
Study NCT06219590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine Iontophoresis
Description: Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.